Sarepta Faces Investor Suit Over Gene Therapy-Linked Deaths

By Emilie Ruscoe · June 27, 2025, 10:09 PM EDT

Biopharmaceutical company Sarepta Therapeutics Inc. is facing a proposed investor class action after the deaths of two patients being treated with one of its therapies prompted regulatory scrutiny, with investors claiming...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In re Sarepta Therapeutics Securities Litigation

Case Number

1:25-cv-05317

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

June 26, 2025